RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of ABUS
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Evaluation of Arbutus Biopharma Corporation stock downgraded after the last trading session.
(Updated on Mar 28, 2024)

Sell candidate since Mar 28, 2024 PDF

The Arbutus Biopharma Corporation stock price fell by -0.769% on the last day (Thursday, 28th Mar 2024) from $2.60 to $2.58. During the last trading day the stock fluctuated 2.35% from a day low at $2.55 to a day high of $2.61. The price has fallen in 5 of the last 10 days and is down by -1.15% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -306 thousand shares and in total, 510 thousand shares were bought and sold for approximately $1.31 million.

The stock lies in the lower part of a wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $2.51 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 11.58% during the next 3 months and, with a 90% probability hold a price between $2.80 and $3.38 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ABUS Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, March 25, 2024, and so far it has risen 3.61%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Arbutus Biopharma Corporation stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $2.72. On a fall, the stock will find some support from the short-term average at $2.54. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss for Arbutus Biopharma Corporation stock

Arbutus Biopharma Corporation finds support from accumulated volume at $2.54 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.0600 between high and low, or 2.35%. For the last week the stock has had daily average volatility of 2.73%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ABUS) For The Upcoming Trading Day Of Monday 1st

For the upcoming trading day on Monday, 1st we expect Arbutus Biopharma Corporation to open at $2.58, and during the day (based on 14 day Average True Range), to move between $2.49 and $2.67, which gives a possible trading interval of +/-$0.0868 (+/-3.36%) up or down from last closing price. If Arbutus Biopharma Corporation takes out the full calculated possible swing range there will be an estimated 6.73% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $2.54 (1.55%) than the resistance at $2.76 (6.98%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Arbutus Biopharma Corporation stock A Buy?

Arbutus Biopharma Corporation holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.

Current score: -2.556 Sell Candidate Downgraded

Predicted Opening Price for Arbutus Biopharma Corporation of Monday, April 1, 2024

Fair opening price April 1, 2024 Current price
$2.58 ( 0%) $2.58

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ABUS

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 2.64 2.33 %
R2 2.62 1.44 %
R1 2.60 0.89 %
Current price: 2.58
Support S1 2.56 -0.89 %
S2 2.54 -1.44 %
S3 2.52 -2.33 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2.91 12.79 %
R2 2.88 11.63 %
R1 2.76 6.98 %
Current price 2.58
Support S1 2.54 -1.55%
S2 2.50 -3.10%
S3 2.49 -3.49%

FAQ

What is the symbol for Arbutus Biopharma Corporation Stock and on which exchange is it traded?
The symbol for Arbutus Biopharma Corporation is ABUS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Arbutus Biopharma Corporation Stock?
Arbutus Biopharma Corporation holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.

How to buy Arbutus Biopharma Corporation Stock?
Arbutus Biopharma Corporation Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Arbutus Biopharma Corporation Stock.

What's the current price of Arbutus Biopharma Corporation Stock?
As of the end of day on the 2024-03-28, the price of an Arbutus Biopharma Corporation (ABUS) share was $2.58.

What is the 52-week high and low for Arbutus Biopharma Corporation Stock?
The 52-week high for Arbutus Biopharma Corporation Stock is $3.15 and the 52-week low is $1.69.

What is the market capitalization of Arbutus Biopharma Corporation Stock?
As of the 2024-03-28, the market capitalization of Arbutus Biopharma Corporation is 463.089M.

When is the next earnings date for Arbutus Biopharma Corporation?
The upcoming earnings date for Arbutus Biopharma Corporation is May 02, 2024.
Click to get the best stock tips daily for free!

About Arbutus Biopharma Corporation

Arbutus Biopharma Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ... ABUS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT